Connecticut 2026 Session Status: In Committee 1 D cosponsors

SB 227 — AN ACT ESTABLISHING A TASK FORCE TO STUDY OVER-THE-COUNTER DIET PILLS AND SUPPLEMENTS AND PROTECT THE PRIVACY OF PRESCRIBERS OF PRESCRIPTION DRUGS FOR REPRODUCTIVE HEALTH CARE AND GENDER-AFFIRMING HEALTH CARE.

Last action — FILE NO. 216

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced February 18, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Stalled 20% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 3 sponsors

    3 primary, 0 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (1 D).

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Bill Text

What changed in the latest version

260 added · 245 removed

Plain-language change summary

The latest version of Bill SB 227 removes some repetitive wording and clarifies the version identifier, making it streamlined. This change helps avoid confusion about which version of the bill is being discussed, ensuring that legislators and the public can easily understand and track its progress. Such clarity in legislative language is important for transparency and effective communication regarding proposed laws.

→
Previous
Latest
General Assembly Raised Bill No.
Senate General Assembly File No.
227 February Session, 2026 LCO No.
216 February Session, 2026 Substitute Senate Bill No.
1615 Referred to Committee on GENERAL LAW Introduced by:
227 Senate, March 30, 2026 The Committee on General Law reported through SEN.
(GL) AN ACT CONCERNING PRESCRIPTION DRUGS AND OVER-THE- COUNTER DIET PILLS AND SUPPLEMENTS.
MARONEY of the 14th Dist., Chairperson of the Committee on the part of the Senate, that the substitute bill ought to pass.
AN ACT ESTABLISHING A TASK FORCE TO STUDY OVER-THE- COUNTER DIET PILLS AND SUPPLEMENTS AND PROTECT THE PRIVACY OF PRESCRIBERS OF PRESCRIPTION DRUGS FOR REPRODUCTIVE HEALTH CARE AND GENDER-AFFIRMING HEALTH CARE.
(NEW) (Effective October 1, 2026) (a) As used in this section:
(Effective from passage) (a) As used in this section:
(1) "Dietary supplement for weight loss or muscle building" means a class of dietary supplement that is labeled, marketed or otherwise representedforthepurposeofachievingweightlossormusclebuilding, but shall not include (A) protein powders, (B) protein drinks, and (C) foods marketed as containing protein unless the protein powder, protein drink or food marketed as containing protein contains an ingredient other than proteinwhich would, considered alone, constitute a dietary supplement for weight loss or muscle building.
(1) "Dietary supplement for weight loss or muscle building" means a class of dietary supplement that is labeled, marketed or otherwise representedforthepurposeofachievingweightlossormusclebuilding, but shall not include (A) protein powders, (B) protein drinks, and (C) foods marketed as containing protein unless the protein powder, protein drink or food marketed as containing protein contains an ingredient other than proteinwhich would, considered alone, constitute a dietary supplement for weight loss or muscle building;
(2) "Over-the-counter diet pill" means a class of drugs labeled, marketed or otherwise represented for the purpose of achieving weight loss that are lawfully sold, transferred or furnished over the counter with or without a prescription pursuant to the federal Food, Drug and Cosmetic Act, 21 USC 301 et seq., as amended from time to time, or regulations adopted thereunder.
and (2) "Over-the-counter diet pill" means a class of drugs labeled, marketed or otherwise represented for the purpose of achieving weight sSB227 / File No.
LCO No.
216 1 sSB227 File No.
1615 1 of 9 Raised Bill No.227 (3) "Retail establishment" means any vendor that, in the regular course of business, sells dietary supplements for weight loss or muscle building or over-the-counter diet pills at retaildirectly to thepublic, and includes, but is not limited to, a pharmacy, grocery store, other retail store and vendor that accepts orders placed by mail, telephone, electronic mail, Internet web site, online catalog or software application.
216 loss that are lawfully sold, transferred or furnished over the counter with or without a prescription pursuant to the federal Food, Drug and Cosmetic Act, 21 USC 301 et seq., as amended from time to time, or regulations adopted thereunder.
(4) "Delivery sale" means any sale of over-the-counter diet pills or dietary supplements for weight loss or muscle building to a consumer if:
(b) There is established a task force to study the sale in the state of dietary supplements for weight loss or muscle building and over-the- counter diet pills.
(A) The consumer submits the order for the sale by means of a telephone or other method of voice transmission, mail or the Internet or other online service, or the seller is otherwise not in the physical presence of the buyer when the request for purchase or order is made;
The task force shall consist of the following members:
or (B) the over-the-counter diet pills or dietary supplements for weight loss or muscle building are delivered to the buyer by common carrier, private delivery service or other method of remote delivery, or the seller is not in the physical presence of the buyer when the buyer obtains possession of the over-the-counter diet pills or dietary supplements for weight loss or muscle building.
(1) Two appointed by the speaker of the House of Representatives, one of whom has expertise in the safety of dietary supplements for weight loss or muscle building and one of whom has expertise in the safety of over-the-counter diet pills;
(5)"Deliveryseller"meansavendor,including anonlineretailer,who makes delivery sales of over-the-counter diet pills or dietary supplements for weight loss or muscle building, and includes, but is not limited to, a person who accepts orders placed by mail, telephone, electronic mail, Internet web site, online catalog or software application.
(2) Two appointed by the president pro tempore of the Senate;
(6) "Proof of legal age" means:
(3) One appointed by the majority leader of the House of Representatives;
(A) A valid driver's license or nondriver identification card issued by the Commissioner of Motor Vehicles, the federal government, any United States territory, commonwealth or possession, the District of Columbia, a state government within the United States or a provincial government of the dominion of Canada, (B) a valid passport issued by the United States government or any other country, (C) an identification card issued by the armed forces of the United States, demonstrating that the individual is at least eighteen years of age, or (D) a student identification card, LCO No.
(4) One appointed by the majority leader of the Senate;
1615 2 of 9 Raised Bill No.227 provided such card indicates the date of birth of the individual.
(5) One appointed by the minority leader of the House of Representatives;
(b) No natural person, firm, corporation, partnership, association, limited liability company or other entity shall sell or offer to sell or give away, as either a retailor wholesale promotion, an over-the-counter diet pill or dietary supplement for weight loss or muscle building in this state to any person under eighteen years of age.
(6) One appointed by the minority leader of the Senate;
Retail establishments shall require proof of legal age for purchase of such products.
(7)The Commissioner ofConsumer Protection,orthecommissioner's designee;
Notwithstanding the provisions of this subsection, proof of legal age need not be required of any individual who reasonably appears to be at least twenty-five years of age, provided such appearance shall not constitute a defense in any proceeding alleging the sale of any over-the- counter diet pills and dietary supplements for weight loss or muscle building to an individual under eighteen years of age.
(8) The Commissioner of Public Health, or the commissioner's designee;
(c) Any person operating a retail establishment may perform a transaction scan as a precondition for the purchase of over-the-counter diet pills or dietary supplements for weight loss or muscle building.
and (9) The executive director of the Commission on Women, Children, Seniors, Equity and Opportunity, who shall serve as chairperson of the task force.
In any instance where the information obtained by the transaction scan fails to match the proof of legal age, or if the transaction scan indicates that the information is false or fraudulent, the attempted transaction shall be denied.
(c) Any member of the task force appointed under subdivision (1), (2), (3), (4), (5) or (6) of subsection (b) of this section may be a member of the General Assembly.
In any proceeding resulting from an alleged violation of this subsection and subsection (b) of this section, it shall be an affirmative defense that (1) the buyer produced proof of legal age apparently issued by a governmental entity, (2) the retail establishment successfully completed a transaction scan, and (3) over-the-counter diet pills or dietary supplements for weight loss or muscle building were sold, delivered or given to such buyer in reasonable reliance upon such identification and transaction scan.
sSB227 / File No.
In evaluating the applicability of such affirmative defense, a court shall take into consideration any written policy adopted and implemented by the seller to effectuate the provisions of this section.
216 2 sSB227 File No.
Use of a transaction scan shall not excuse any person operating a retail establishment from the exercise of reasonable diligence otherwise required by this section.
216 (d) All initial appointments to the task force shall be made not later thanthirty daysafter theeffective date ofthis section.Any vacancy shall be filled by the appointing authority.
LCO No.
(e) The chairperson of the task force shall schedule the first meeting of the task force, which shall be held not later than sixty days after the effective date of this section.
1615 3 of 9 Raised Bill No.227 (d) A retail establishment or employee of such establishment may electronically or mechanically record and maintain only the information from a transaction scan necessary to effectuate this section.
(f) The administrative staff of the joint standing committee of the General Assembly having cognizance of matters relating to general law shall serve as administrative staff of the task force.
Such information shall be limited to the following:
(g) Not later than January 1, 2027, the task force shall submit a report on its findings and recommendations to the joint standing committee of the General Assembly having cognizance of matters relating to general law, in accordance with the provisions of section 11-4a of the general statutes.
(1) Name, (2) date of birth, (3) driver's license or nondriver identification number, and (4) expiration date.
The report shall include, but need not be limited to, research related to the safety of dietary supplements for weight loss or muscle building andover-the-counter dietpillsby age ofusers,whetherthesale to minors of such supplements or pills should be restricted and best practices in other states for regulation of such supplements or pills.
A retail establishment or employee of such establishment shall only use the information recorded and maintained through a transaction scan for the purpose of complying with the provisions of this section.
No retail establishment or employee of such establishment shall sell or disseminate the information recorded during such a scan to any third person, including, but not limited to, for the purposes of any advertising, marketing or promotional activities.
Notwithstanding the restrictions imposed by this subsection, such records may be released pursuant to a court-ordered subpoena or pursuant to any other applicable law that specifically authorizes the release of such information.
(e) A delivery seller, including an online retailer, who mails or ships over-the-counter diet pills or dietary supplements for weight loss or muscle building to consumers (1) shall not sell, deliver or cause to be delivered any over-the counter diet pills or dietary supplements for weight loss or muscle building to a person under eighteen years of age;
and (2) shall use a method of mailing or shipping (A) that requires the purchaser placing the delivery sale order, or an adult who is at least eighteenyearsofage,tosigntoacceptdeliveryoftheshippingcontainer at the delivery address;
and (B) that requires the person who signs to accept delivery of the order to provide proof of legal age.
(f) The Commissioner of Consumer Protection may, after notice and a hearing in accordance with chapter 54 of the general statutes, impose a civil penalty of not more than one thousand dollars for each separate violation of the requirements of this section.
Upon notice to the defendant of not less than five days, the commissioner or the Attorney General may apply to the Superior Court for a temporary or permanent injunction restraining any person from violating any provision of this LCO No.
1615 4 of 9 Raised Bill No.227 section, irrespective of whether or not there exists an adequate remedy at law.
If the court determines that the defendant has violated the provisions of this section, the court may issue an injunction enjoining and restraining any further violations, without requiring proof that any person has, in fact, been injured or damaged thereby.
(g) When determining whether an over-the-counter diet pill or dietary supplement is labeled, marketed or otherwise represented for the purpose of achieving weight loss or muscle building, the court shall consider, but is not limited to, the following factors:
Show all 113 changed rows (73 more)
Previous
Latest
(1) Whether the product contains (A) an ingredient approved by the federal Food and Drug Administration for weight loss or muscle building, (B) a steroid, or (C) creatine, green tea extract,raspberry ketone, garcinia cambogia or green coffee bean extract;
(2) whether the product's labeling or marketing bears statements or images that express or imply that the product will help (A) modify, maintain or reduce body weight, fat, appetite, overall metabolism or the process by which nutrients are metabolized, or (B) maintain or increase muscle or strength;
(3) whether the product or its ingredients are otherwise represented for the purpose of achieving weight loss or building muscle;
or (4) whether the retailer has categorized the dietary supplement for weight loss or muscle building by (A) placing signs, categorizing, or tagging the supplement with statements described in subdivision (2) of this subsection, (B) grouping the supplements with other weight loss or muscle building products in a display, advertisement, webpage, or area of the store, or (C) otherwise representing that the product is for weight loss or muscle building.
(a) As used in this section, ["reproductive health care services" and "gender-affirming health care services" have the same meanings as provided] "legally protected health care activity" means the provision of LCO No.
(a) As used in this section, "reproductive health care services" and "gender-affirming health care services" have the same meanings as provided in section 52-571m.
1615 5 of 9 Raised Bill No.227 reproductive health care services and gender-affirming health care services, as defined in section 52-571m.
(b) Notwithstanding any provision of this chapter, the Commissioner of Consumer Protection and the Commission of Pharmacy shall not deny the eligibility of an applicant for a license, permit or registration under this chapter based on pending disciplinary action, an unresolved complaint, [or] the imposition of disciplinary action or other adverse action against the applicant by a duly authorized professional disciplinary agency of another state, the District of Columbia, [or] a sSB227 / File No.
(b) Notwithstanding any provision of this chapter, the Commissioner of Consumer Protection and the Commission of Pharmacy shall not deny the eligibility of an applicant for a license, permit or registration under this chapter based on pending disciplinary action, an unresolved complaint, [or] the imposition of disciplinary action or other adverse action against the applicant by a duly authorized professional disciplinary agency of another state, the District of Columbia, [or] a commonwealth, territory or possession of the United States or any federal entity that is based solely on the alleged provision or practice of, receipt of, assistance in provision or receipt of, material support for, or any theory of vicarious, joint, several or conspiracy liability derived therefrom, [reproductive healthcare servicesor gender-affirming health care services that are] legally protected health care activity that is permitted under the laws of this state and [were] was provided in accordance with the standard of care applicable to such services.
216 3 sSB227 File No.
216 commonwealth, territory or possession of the United States or any federal entity that is based solely on the alleged provision of, receipt of, assistance in provision or receipt of, material support for, or any theory of vicarious, joint, several or conspiracy liability derived therefrom, reproductive health care services or gender-affirming health care services that are permitted under the laws of this state and were provided in accordance with the standard of care applicable to such services.
(c) Notwithstanding any provision of this chapter, the Commissioner of Consumer Protection and the Commission of Pharmacy shall not impose disciplinary action against any person licensed, permitted or registered pursuant to the provisions of this chapter based on pending disciplinary action, an unresolved complaint, [or] the imposition of disciplinary action or other adverse action against the applicant by a duly authorized professional disciplinary agency of another state, the District of Columbia, [or] a commonwealth, territory or possession of the United States or any federal entity that is based solely on the alleged provision or practice of, receipt of, assistance in provision or receipt of, LCO No.
(c) Notwithstanding any provision of this chapter, the Commissioner of Consumer Protection and the Commission of Pharmacy shall not impose disciplinary action against any person licensed, permitted or registered pursuant to the provisions of this chapter based on pending disciplinary action, an unresolved complaint, [or] the imposition of disciplinary action or other adverse action against the applicant by a duly authorized professional disciplinary agency of another state, the District of Columbia, [or] a commonwealth, territory or possession of the United States or any federal entity that is based solely on the alleged provision of, receipt of, assistance in provision or receipt of, material support for, or any theory of vicarious, joint, several or conspiracy liability derived therefrom, reproductive health care services or gender- affirming health care services that are permitted under the laws of this state and were provided in accordance with the standard of care applicable to suchservices.
1615 6 of 9 Raised Bill No.227 material support for, or any theory of vicarious, joint, several or conspiracy liability derived therefrom, [reproductive health care services or gender-affirming health care services that are] legally protected health care activity that is permitted under the laws of this state and [were] was provided in accordance with the standard of care applicable to suchservices.
Sec.
sSB227 / File No.
216 4 sSB227 File No.
216 Sec.
Such transmitted order shall contain the name of the prescribing practitioner and shall be treated as a written prescription for purposes of sections 20-570 to 20-625, inclusive, except that, to the extent allowable under federal law, at the prescribing practitioner's request, the written or electronic prescription for drugs related to legally protected health care activity, as defined in section 20-579a, as amended by this act, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name and signature of the prescribing practitioner.
Such transmitted order shall contain the name of the prescribing practitioner and shall be treated as a written prescription for purposes of sections 20-570 to 20-625, inclusive, except that, to the extent allowable under federal law, at the prescribing practitioner's request, the written or electronic prescription for drugs related to reproductive health care services or gender-affirming health care services, as defined in section 52-571m, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name and signature of the prescribing practitioner.
LCO No.
(NEW) (g) Notwithstanding the provisions of subsections (a) to (c), inclusive, of this section, to the extent allowable under federal law, at the prescribing practitioner's request, the written or electronic prescription for drugs related to reproductive health care services or gender-affirming health care services, as defined in section 52-571m, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name and signature of the prescribing practitioner.
1615 7 of 9 Raised Bill No.
227 (NEW) (g) Notwithstanding the provisions of subsections (a) to (c), inclusive, of this section, to the extent allowable under federal law, at the prescribing practitioner's request, the written or electronic prescription for drugsrelated to legally protected health care activity, as defined in section 20-579a, as amended by this act, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name and signature of the prescribing practitioner.
(NEW) (d) Notwithstanding the provisions of subsections (a) to (c), inclusive, of this section, to the extent allowable under federal law, at the prescribing practitioner's request, the written or electronic prescription and label of each prescription for drugs related to legally protected health care activity, as defined in section 20-579a, as amended by this act, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name of the prescribing practitioner.
(NEW) (d) Notwithstanding the provisions of subsections (a) to (c), inclusive, of this section, to the extent allowable under federal law, at the prescribing practitioner's written, electronic or verbal request to the sSB227 / File No.
216 5 sSB227 File No.
216 dispensing pharmacy, thedispensedlabelofeachprescriptiondrug that is not a controlled substance and relates to reproductive health care services or gender-affirming health care services, as defined in section 52-571m, shall include the name and address of the prescribing and dispensing health care practice or facility instead of the name of the prescribing practitioner.
Section 1 October 1, 2026 New section Sec.
Section 1 from passage New section Sec.
5 October 1, 2026 20-617(d) Statement of Purpose:
5 October 1, 2026 20-617(d) GL Joint Favorable Subst.
To prohibit marketing of certain weight loss pills and supplements to minors and enact legal and privacy protections for prescribers of prescription drugs for reproductive and gender-affirming health care.
sSB227 / File No.
LCO No.
216 6 sSB227 File No.
1615 8 of 9 Raised Bill No.
216 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.
227 [Proposed deletions are enclosed in brackets.
In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.
Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.] LCO No.
Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.
1615 9 of 9
OFA Fiscal Note State Impact:
None Municipal Impact:
None Explanation The bill establishes a task force to study the sale of dietary supplements resulting in no fiscal impact to the state because the task force has the expertise to meet the requirements of the bill.
The bill also makes various changes to pharmacy statutes concerning reproductive and gender-affirming health care resulting in no fiscal impact to the state.
The Out Years State Impact:
None Municipal Impact:
None sSB227 / File No.
216 7 sSB227 File No.
216 OLR Bill Analysis sSB 227 AN ACT ESTABLISHING A TASK FORCE TO STUDY OVER-THE- COUNTER DIET PILLS AND SUPPLEMENTS AND PROTECT THE PRIVACY OF PRESCRIBERS OF PRESCRIPTION DRUGS FOR REPRODUCTIVE HEALTH CARE AND GENDER-AFFIRMING HEALTH CARE.
SUMMARY This bill establishes a task force to study the sale of dietary supplements for weight loss or muscle building and over-the-counter diet pills (§ 1).
It also expands current law that prohibits the Department of Consumer Protection and the Commission on Pharmacy from denying a pharmacy-related license, permit, or registration, or imposing discipline on the holder of such a pharmacy-related credential, because of a pending or imposed disciplinary action or unresolved complaint in another U.S.
state or jurisdiction related to reproductive and gender- affirming health care that is allowed in Connecticut.
Specifically, it applies these prohibitions to (1) other types of adverse actions taken in another jurisdiction for these reasons and (2) any of these actions taken by a federal entity (§ 2).
Additionally, to the extent permitted by federal law, the bill requires a prescription order for a drug related to reproductive health or gender- affirming health care, at the prescriber’s request, to include the prescribing and dispensing practice’s or facility’s name and address instead of the prescriber’s name and signature.
This same provision applies to the dispensed label for one of these drugs unless it is a controlled substance (§§ 3-5).
By law, “reproductivehealth care services” include medical, surgical, counseling, and referral services relating to the human reproductive sSB227 / File No.
216 8 sSB227 File No.
216 system.
“Gender-affirming health care services” generally are supplies, care and services of a medical, behavioral health, mental health, surgical, psychiatric, therapeutic, diagnostic, preventative, rehabilitative, or supportive nature, including medication for treating gender dysphoria and gender incongruence.
It does not include conversion therapy (CGS § 52-571m).
EFFECTIVE DATE:
October 1, 2026, except the provisions on the task force take effect upon passage.
§ 1 — TASK FORCE The bill establishes an 11-person task force to study the sale ofdietary supplements for weight loss or muscle building and over-the-counter diet pills.
The study must address:
1.
dietary supplements labeled, marketed, or represented as achieving weight loss or muscle building, but not (a) protein powders or drinks or (b) foods marketed as having protein, unless the powder, food, or drink has another ingredient that on its own is a dietary supplement for weight loss or muscle building, and 2.
over-the-counter diet pills that are (a) drugs labeled, marketed, or represented as achieving weight loss or muscle building and (b) available over the counter with or without a prescription under federal law.
The bill requires the task force to consist of:
1.
the Commission on Women, Children, Seniors, Equity and Opportunity’s executive director, who serves as task force chairperson;
2.
the commissioners of consumer protection and public health, or their designees;
3.
two members appointed by the House speaker, one with expertise in the safety of applicable dietary supplements and one sSB227 / File No.
216 9 sSB227 File No.
216 with expertise in the safety of applicable over-the-counter pills;
4.
two members appointed by the Senate president pro tempore;
and 5.
one each appointed by the House and Senate majority and minority leaders.
The bill allows appointed members to be legislators, requires appointments to be made within 30 days after the bill’s passage, and directs the appointing authorities to fill vacancies.
The chairperson must schedule and hold the first meeting within 60 days after the bill’s passage, and the General Law Committee administrative staff serves as the task force’s administrative staff.
The bill requires the task force to report to the General Law Committee by January 1, 2027.
The report must include research on the safety of these items by user age, whether their sale to minors should be restricted, and other states’ best practices for regulating them.
COMMITTEE ACTION General Law Committee Joint Favorable Substitute Yea 19 Nay 2 (03/16/2026) sSB227 / File No.
216 10
⬇ Download PDF
View plain text versions (3)

Action History

  1. FILE NO. 216

  2. SENATE CALENDAR NUMBER 171

  3. FAV. RPT., TAB. FOR CAL., SEN.

  4. RPTD. OUT OF LCO

  5. REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 03/30/26

  6. FILED WITH LCO

  7. Joint Favorable Substitute

  8. PUBLIC HEARING 0223

  9. REF. TO JOINT COMM. ON General Law

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

3 sponsors · 0 co-sponsors · 184 not signed on

Sponsors (3)

Co-sponsors (0)

None.

Not signed on (184)

184 members have not signed on to this bill.

Show all 184 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 227?
SB 227 is sponsored by Morrin Bello, Mccarthy Vahey, and Julie Kushner (Democratic).
What is the current status of SB 227?
This bill is in committee in the Senate. Introduced February 18, 2026. It must pass committee before a floor vote.
Where can I track SB 227?
Track SB 227 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 227

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 227

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →